title: A review of cost-effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?
abstract: Overactive bladder (OAB) syndrome is a prevalent condition known to have a substantial impact on a patient's quality of life (QoL). Treatment options are numerous and include pharmacotherapy and other non-invasive measures, as well as more or less invasive interventions. Antimuscarinics are the cornerstone of medical management. Given that millions of patients suffer OAB symptoms worldwide and there is abundance of treatment options available, selecting the treatment strategy that offers the best balance of QoL improvement to resources spent in achieving it becomes crucial in the current situation of healthcare budget restrictions worldwide. This review summarizes available evidence on economic analyses of OAB treatments aimed at identifying the most cost-effective in terms of improving QoL.
authors: Department of Urology, Patras University Hospital, Building A, 26500, Patras, Greece.
authors: Konstantinos
authors: K
authors: Giannitsas
authors: Anastasios
authors: A
authors: Athanasopoulos
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D018727:Muscarinic Antagonists / Q000191:economics / Q000627:therapeutic use*; D011788:Quality of Life; D053201:Urinary Bladder, Overactive / Q000191:economics / Q000628:therapy*
chemical_list: D018727:Muscarinic Antagonists
keywords: antimuscarinics; cost–effectiveness; overactive bladder; quality of life; treatment; urge incontinence